New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:31 EDTRGRXRegeneRx receives notice of allownace from U.S. Patent Office for new indication
RegeneRx Biopharmaceuticals has received a Notice of Allowance of a U.S. patent for the use of Thymosin beta 4, certain fragments, isoforms, derivatives and analogues to treat patients with glaucoma and elevated intraocular pressure. Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve. This nerve carries visual information from the eye to the brain. In most cases, damage to the optic nerve is due to increased pressure in the eye, known as intraocular pressure. Glaucoma is the second most common cause of blindness in the United States. The patent will expire in 2026.
News For RGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
11:41 EDTRGRXRegeneRx receives Australian patent acceptance for TB4 peptide fragment
RegeneRx announced that the Australian government has issued a Notice of Acceptance for a patent for a key peptide fragment of Thymosin beta 4. The patent claims are directed to the composition of matter and methods of use, including inhibiting tissue damage caused by ultraviolet radiation and promoting neurite outgrowth and neuron survival, among others. The patent expiry is expected to be 2029.
July 17, 2015
11:01 EDTRGRXRegeneRx's GtreeBNT receives Korean approval to conduct clinical trial
Subscribe for More Information
July 14, 2015
12:48 EDTRGRXUSPTO issues notice of allowance for patent covering administration of TB4
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use